Eversept Partners LP Has $15.71 Million Stake in Ascendis Pharma A/S (NASDAQ:ASND)

Share on StockTwits

Eversept Partners LP grew its position in Ascendis Pharma A/S (NASDAQ:ASND) by 32.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 136,397 shares of the biotechnology company’s stock after acquiring an additional 33,101 shares during the quarter. Ascendis Pharma A/S accounts for about 4.5% of Eversept Partners LP’s holdings, making the stock its 8th largest position. Eversept Partners LP owned 0.32% of Ascendis Pharma A/S worth $15,706,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in ASND. FMR LLC raised its holdings in shares of Ascendis Pharma A/S by 11.6% in the 1st quarter. FMR LLC now owns 4,692,707 shares of the biotechnology company’s stock worth $552,332,000 after buying an additional 489,461 shares in the last quarter. Vivo Capital LLC increased its holdings in Ascendis Pharma A/S by 0.6% during the 2nd quarter. Vivo Capital LLC now owns 2,060,135 shares of the biotechnology company’s stock valued at $237,225,000 after purchasing an additional 13,303 shares in the last quarter. Marshall Wace North America L.P. increased its holdings in Ascendis Pharma A/S by 56.4% during the 1st quarter. Marshall Wace North America L.P. now owns 1,161,476 shares of the biotechnology company’s stock valued at $136,706,000 after purchasing an additional 418,717 shares in the last quarter. Artisan Partners Limited Partnership increased its holdings in Ascendis Pharma A/S by 208.2% during the 1st quarter. Artisan Partners Limited Partnership now owns 1,131,107 shares of the biotechnology company’s stock valued at $133,131,000 after purchasing an additional 764,160 shares in the last quarter. Finally, Sofinnova Investments Inc. increased its holdings in Ascendis Pharma A/S by 10.1% during the 2nd quarter. Sofinnova Investments Inc. now owns 1,099,824 shares of the biotechnology company’s stock valued at $126,645,000 after purchasing an additional 101,286 shares in the last quarter.

ASND traded down $2.22 during mid-day trading on Friday, reaching $102.35. The stock had a trading volume of 1,285 shares, compared to its average volume of 202,170. The stock has a market capitalization of $4.44 billion, a P/E ratio of -27.65 and a beta of 0.64. The company has a debt-to-equity ratio of 0.05, a quick ratio of 11.59 and a current ratio of 11.59. The firm’s fifty day simple moving average is $113.12 and its two-hundred day simple moving average is $115.49. Ascendis Pharma A/S has a 52 week low of $53.21 and a 52 week high of $133.96.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, August 28th. The biotechnology company reported ($1.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.32) by ($0.08). The firm had revenue of $3.61 million during the quarter, compared to the consensus estimate of $0.68 million. Ascendis Pharma A/S had a negative net margin of 932.52% and a negative return on equity of 35.99%. As a group, analysts expect that Ascendis Pharma A/S will post -5.31 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on ASND shares. Wedbush reaffirmed a “buy” rating and set a $223.00 price target on shares of Ascendis Pharma A/S in a report on Friday, June 28th. BidaskClub cut Ascendis Pharma A/S from a “sell” rating to a “strong sell” rating in a report on Thursday. JPMorgan Chase & Co. raised their price target on Ascendis Pharma A/S from $143.00 to $152.00 and gave the company an “overweight” rating in a report on Thursday, August 29th. Canaccord Genuity raised their price target on Ascendis Pharma A/S from $133.00 to $144.00 and gave the company a “buy” rating in a report on Friday, May 31st. Finally, Zacks Investment Research raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Tuesday, August 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $153.29.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Further Reading: Overbought

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Research Analysts’ Downgrades for September, 20th
Research Analysts’ Downgrades for September, 20th
Stock Analysts’ Upgrades for September, 20th
Stock Analysts’ Upgrades for September, 20th
Nissan Motor  Lowered to “Sell” at Zacks Investment Research
Nissan Motor Lowered to “Sell” at Zacks Investment Research
Zacks Investment Research Lowers NicOx  to Hold
Zacks Investment Research Lowers NicOx to Hold
easyJet  Stock Rating Reaffirmed by Credit Suisse Group
easyJet Stock Rating Reaffirmed by Credit Suisse Group
JSR CORP/ADR  Downgraded by Jefferies Financial Group
JSR CORP/ADR Downgraded by Jefferies Financial Group


© 2006-2019 Ticker Report